icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes
1-4 in HIV-HCV Coinfection: The ALLY-2 Study

 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Wyles DL,1 Ruane P,2 Sulkowski MS,3 Dieterich D,4 Luetkemeyer AF,5 Morgan TR,6 Sherman KE,7 Liu Z,8 Noviello S,8 Ackerman P8
1University of California, San Diego, CA, USA; 2Ruane Medical and Liver Health Institute, Los Angeles, CA, USA; 3Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4Icahn School of Medicine at Mount Sinai, New York, NY, USA; 5University of California and San Francisco General Hospital, San Francisco, CA, USA; 6VA Long Beach Healthcare System, Long Beach, CA, USA; 7University of Cincinnati College of Medicine, Cincinnati, OH, USA; 8Bristol-Myers Squibb, Princeton, NJ, USA.

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

Allowed antiretrovirals (ARVs) encompassed 9/10 of the DHHS-recommended (http://aidsinfo.nih.gov/guidelines) and 12/13 of the EACS-recommended (http://www.eacsociety.org/) first-line regimens

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif